American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM): Annual Meeting
Conference Coverage
Novel myasthenia gravis therapies bring opportunities, challenges
Minimal disease manifestation is meaningful for patients, but should be weighed against potential side effects.
Conference Coverage
Newly approved myasthenia gravis drug shows sustained benefits in early responders
“This self-administered medication allows patients to be more independent and can even travel since it is not dependent on an infusion center.”
Conference Coverage
Chemotherapy-induced peripheral neuropathy tied to compromised executive function
Chemotherapy-related mobility declines in CIPN survivors are likely due to both neuromuscular and executive dysfunction.
Conference Coverage
Artificial intelligence presents opportunities, challenges in neurologic practice
Programs can generate health care and research content, but require close supervision and an attitude of ‘trust, but verify.’
Conference Coverage
U.S. study finds unexpectedly high prevalence of myasthenia gravis
A study of the NIH All of Us database shows a higher prevalence of myasthenia gravis than what has been reported in previous studies.
Conference Coverage
U.S. study finds unexpectedly high prevalence of myasthenia gravis
A study of the NIH All of Us database shows a higher prevalence of myasthenia gravis than what has been reported in previous studies.
Conference Coverage
‘Hidden’ cognitive impairments in DMD may worsen outcomes
Long waits for neuropsychiatric evaluations make it difficult to get help, but an NIH tool may help.
Conference Coverage
First new treatment in 30 years for rare disease is effective, tolerable, convenient
A new subcutaneous injectable showed efficacy and tolerability in patients with chronic inflammatory demyelinating polyneuropathy.
Conference Coverage
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
“What’s really striking, and in my mind the most impressive, is that when you follow these patients out 3 or 4 years ... you see there is this...
Conference Coverage
Genetic therapies bring change to neurology clinics
Advancements are set to alter the approach to some patients and inspire a demand for genetic counselors in neuromuscular clinics.
Conference Coverage
In myasthenia gravis, antibodies pass open-label tests
New class of therapies interfere with IgG recycling and have similar efficacy across multiple cycles of treatment.
Conference Coverage
POTS heterogeneity requires individualized treatment
AUSTIN, TEX. – Despite an increasing awareness of its prevalence, POTS often still goes unrecognized and requires a therapeutic approach that...
Conference Coverage
Don’t miss neuromuscular complications of cancer immunotherapy
AUSTIN, TEX. – “Timing of onset is a critical component to assist in identifying immune checkpoint inhibitor-associated versus non-immune...
Conference Coverage
Ataluren shows real-world benefit for nonsense mutation Duchenne muscular dystrophy
AUSTIN, TEX. – Side effects in children taking ataluren were primarily gastrointestinal upset, headache, and...
Conference Coverage
AChR autoantibody subtype testing may improve accuracy of myasthenia gravis evaluations
AUSTIN, TEX. – Testing for binding antibodies and for modulating antibodies may be more accurate than testing for either subtype alone.